RA Capital Nexus Fund II, L.P. — SEC Form 4 filings
SEC reporting owner CIK 1825376. 43 Form 4 filings on record with FilingPulse; latest filed 2026-07-22.
Transaction summary — filings shown
Covers all 43 filings on record, filed 2024-02-13 to 2026-07-22. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 28 legs across 12 filings — 33,375,515 shares, $272,987,816 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 2 legs across 1 filing — 3,525,094 shares, $3,807,102 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 72.
- Largest priced transaction: purchase of 1,200,000 shares @ $44.75 ($53,700,000) in Janux Therapeutics, Inc., filed 2024-10-22.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | Director | 6 | 5 legs · 2,024,041 sh · $79,042,965 | — | 7 |
| PepGen Inc. (PEPG) | Director | 5 | 2 legs · 11,932,593 sh · $57,212,790 | — | 3 |
| Hemab Therapeutics Holdings, Inc. (COAG) | Director | 1 | 6 legs · 2,840,429 sh · $52,222,946 | — | 9 |
| Climb Bio, Inc. (CLYM) | Director | 8 | 5 legs · 13,330,218 sh · $50,732,442 | — | 10 |
| LENZ Therapeutics, Inc. (LENZ) | Director | 3 | 2 legs · 998,009 sh · $15,000,075 | — | 9 |
| ARS Pharmaceuticals, Inc. (SPRY) | Director | 4 | 3 legs · 1,401,299 sh · $13,289,410 | — | 3 |
| Boundless Bio, Inc. (BOLD) | 10% owner | 1 | 2 legs · 312,500 sh · $5,000,000 | — | 6 |
| AN2 Therapeutics, Inc. (ANTX) | 10% owner | 1 | — | 2 legs · 3,525,094 sh · $3,807,102 | — |
| Werewolf Therapeutics, Inc. (HOWL) | Director, 10% owner | 2 | 3 legs · 536,426 sh · $487,188 | — | 1 |
| Freenome, Inc. (FRNM) | Director | 1 | — | — | 7 |
+3 more issuers among the filings shown — every filing appears in the table below.
Form 4 filings — RA Capital Nexus Fund II, L.P.
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-07-22 | 4 | Freenome, Inc. (FRNM) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., RA Capital Nexus Fund III, L.P., Kolchinsky Peter, Shah Rajeev M. | Grant/award (A): 6,561,711 · Grant/award (A): 970,950 · Grant/award (A): 553,703 · Grant/award (A): 908,103 · Grant/award (A): 367,427 · Grant/award (A): 4,918,411 @ $10 · +1 more | EDGAR |
| 2026-07-01 | 4 | Climb Bio, Inc. (CLYM) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., RA Capital Nexus Fund III, L.P., Kolchinsky Peter, Shah Rajeev M. | Grant/award (A): 70,284 (derivative) @ $0 | EDGAR |
| 2026-06-26 | 4 | ARS Pharmaceuticals, Inc. (SPRY) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter, Shah Rajeev M. | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2026-06-22 | 4 | PepGen Inc. (PEPG) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter, Shah Rajeev M. | Grant/award (A): 34,000 (derivative) @ $0 | EDGAR |
| 2026-06-22 | 4 | Acrivon Therapeutics, Inc. (ACRV) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter, Shah Rajeev M. | Grant/award (A): 20,275 (derivative) @ $0 | EDGAR |
| 2026-06-15 | 4 | LENZ Therapeutics, Inc. (LENZ) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter, Shah Rajeev M. | Grant/award (A): 22,100 (derivative) @ $0 | EDGAR |
| 2026-06-12 | 4 | Janux Therapeutics, Inc. (JANX) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter, Shah Rajeev M. | Grant/award (A): 5,500 @ $0 · Grant/award (A): 15,500 (derivative) @ $0 | EDGAR |
| 2026-06-08 | 4 | Climb Bio, Inc. (CLYM) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., RA Capital Nexus Fund III, L.P., Kolchinsky Peter, Shah Rajeev M. | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2026-06-05 | 4 | Acumen Pharmaceuticals, Inc. (ABOS) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter, Shah Rajeev M. | Grant/award (A): 35,500 @ $0 · Grant/award (A): 53,250 (derivative) @ $0 | EDGAR |
| 2026-05-20 | 4 | Acrivon Therapeutics, Inc. (ACRV) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter, Shah Rajeev M. | Grant/award (A): 9,366 @ $0 | EDGAR |
| 2026-05-06 | 4 | Hemab Therapeutics Holdings, Inc. (COAG) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund IV, L.P., Kolchinsky Peter, Shah Rajeev M. | Conversion (C): 3,607,846 · Conversion (C): 1,009,052 · Conversion (C): 221,188 · Purchase (P): 2,541,250 @ $18 · Purchase (P): 133,750 @ $18 · Purchase (P): 87,143 @ $24.59 · +9 more | EDGAR |
| 2026-04-29 | 4 | Climb Bio, Inc. (CLYM) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., RA Capital Nexus Fund III, L.P., Kolchinsky Peter, Shah Rajeev M. | Grant/award (A): 2,106,000 (derivative) @ $9.50 | EDGAR |
| 2026-04-23 | 4 | Acrivon Therapeutics, Inc. (ACRV) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter, Shah Rajeev M. | Grant/award (A): 3,888,888 @ $1.80 | EDGAR |
| 2026-03-18 | 4 | Acumen Pharmaceuticals, Inc. (ABOS) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter, Shah Rajeev M. | Grant/award (A): 6,060,606 @ $3.30 | EDGAR |
| 2026-01-07 | 4 | Climb Bio, Inc. (CLYM) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., RA Capital Nexus Fund III, L.P., Kolchinsky Peter, Shah Rajeev M. | Purchase (P): 7,111 @ $3.50 | EDGAR |
| 2025-12-15 | 4 | Climb Bio, Inc. (CLYM) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., RA Capital Nexus Fund III, L.P., Kolchinsky Peter, Shah Rajeev M. | Disposition to issuer (D): 20,440,000 @ $0 · Purchase (P): 213,099 @ $2.18 · Purchase (P): 101,462 @ $2.86 · Grant/award (A): 20,440,000 (derivative) | EDGAR |
| 2025-09-30 | 4 | PepGen Inc. (PEPG) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter, Shah Rajeev M. | Purchase (P): 9,375,000 @ $3.20 | EDGAR |
| 2025-06-27 | 4 | ARS Pharmaceuticals, Inc. (SPRY) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter, Shah Rajeev M. | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2025-06-17 | 4 | Acrivon Therapeutics, Inc. (ACRV) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter, Shah Rajeev M. | Grant/award (A): 20,275 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | Janux Therapeutics, Inc. (JANX) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter, Shah Rajeev M. | Grant/award (A): 3,750 @ $0 · Grant/award (A): 11,667 (derivative) @ $0 | EDGAR |
| 2025-06-11 | 4 | LENZ Therapeutics, Inc. (LENZ) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter, Shah Rajeev M. | Grant/award (A): 13,500 (derivative) @ $0 | EDGAR |
| 2025-06-06 | 4 | PepGen Inc. (PEPG) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter, Shah Rajeev M. | Grant/award (A): 16,000 (derivative) @ $0 | EDGAR |
| 2025-06-05 | 4 | Climb Bio, Inc. (CLYM) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., RA Capital Nexus Fund III, L.P., Kolchinsky Peter, Shah Rajeev M. | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2025-06-05 | 4 | Acumen Pharmaceuticals, Inc. (ABOS) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter, Shah Rajeev M. | Grant/award (A): 12,800 @ $0 · Grant/award (A): 19,500 (derivative) @ $0 | EDGAR |
| 2025-05-14 | 4 | Werewolf Therapeutics, Inc. (HOWL) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter, Shah Rajeev M. | Purchase (P): 320,913 @ $0.86 · Purchase (P): 52,974 @ $0.98 · Purchase (P): 162,539 @ $0.98 | EDGAR |
| 2025-03-07 | 4 | Janux Therapeutics, Inc. (JANX) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter, Shah Rajeev M. | Purchase (P): 304,287 @ $30.56 · Purchase (P): 37,455 @ $31.30 · Purchase (P): 372,093 @ $30.78 · Purchase (P): 110,206 @ $31.02 | EDGAR |
| 2024-10-22 | 4 | Janux Therapeutics, Inc. (JANX) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter, Shah Rajeev M. | Purchase (P): 1,200,000 @ $44.75 | EDGAR |
| 2024-08-13 | 4 | AN2 Therapeutics, Inc. (ANTX) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter, Shah Rajeev M. | Sale (S): 3,410,335 @ $1.08 · Sale (S): 114,759 @ $1.08 | EDGAR |
| 2024-07-01 | 4 | Eliem Therapeutics, Inc. (ELYM) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., RA Capital Nexus Fund III, L.P., Kolchinsky Peter, Shah Rajeev M. | Grant/award (A): 973,000 · Grant/award (A): 2,479,872 · Grant/award (A): 1,807,000 · Purchase (P): 11,949,171 @ $3.84 · Purchase (P): 1,059,375 @ $3.84 | EDGAR |
| 2024-06-28 | 4 | Janux Therapeutics, Inc. (JANX) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter, Shah Rajeev M. | Grant/award (A): 2,500 @ $0 · Grant/award (A): 8,350 (derivative) @ $0 | EDGAR |
| 2024-06-28 | 4 | Eliem Therapeutics, Inc. (ELYM) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., Kolchinsky Peter, Shah Rajeev M. | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2024-06-24 | 4 | ARS Pharmaceuticals, Inc. (SPRY) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter, Shah Rajeev M. | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2024-06-24 | 4 | Acrivon Therapeutics, Inc. (ACRV) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter, Shah Rajeev M. | Grant/award (A): 20,275 (derivative) @ $0 | EDGAR |
| 2024-06-21 | 4 | PepGen Inc. (PEPG) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter, Shah Rajeev M. | Grant/award (A): 13,000 (derivative) @ $0 | EDGAR |
| 2024-06-10 | 4 | Acumen Pharmaceuticals, Inc. (ABOS) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter, Shah Rajeev M. | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2024-05-24 | 4 | Werewolf Therapeutics, Inc. (HOWL) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter, Shah Rajeev M. | Grant/award (A): 17,500 (derivative) @ $0 | EDGAR |
| 2024-04-15 | 4 | Acrivon Therapeutics, Inc. (ACRV) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter, Shah Rajeev M. | Grant/award (A): 3,530,000 @ $8.50 | EDGAR |
| 2024-04-04 | 4 | Boundless Bio, Inc. (BOLD) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter, Shah Rajeev M. | Conversion (C): 1,587,912 · Purchase (P): 296,875 @ $16 · Conversion (C): 280,219 · Purchase (P): 15,625 @ $16 · Conversion (C): 17,000,000 (derivative) @ $0 · Conversion (C): 3,000,000 (derivative) @ $0 · +2 more | EDGAR |
| 2024-03-27 | 4 | ARS Pharmaceuticals, Inc. (SPRY) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter, Shah Rajeev M. | Purchase (P): 437,600 @ $9.06 · Purchase (P): 457,745 @ $9.55 · Purchase (P): 505,954 @ $9.79 | EDGAR |
| 2024-03-25 | 4 | LENZ Therapeutics, Inc. (LENZ) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter, Shah Rajeev M. | Grant/award (A): 2,386,301 · Grant/award (A): 694,755 · Grant/award (A): 164,729 · Purchase (P): 933,038 @ $15.03 · Purchase (P): 64,971 @ $15.03 · Grant/award (A): 54,582 (derivative) · +3 more | EDGAR |
| 2024-03-06 | 4 | Janux Therapeutics, Inc. (JANX) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter, Shah Rajeev M. | Purchase (P): 1,397,849 (derivative) @ $46.50 | EDGAR |
| 2024-02-20 | 4 | Icosavax, Inc. (ICVX) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter, Shah Rajeev M. | Code (U): 5,543 · Code (U): 5,324,897 · Code (U): 638,668 · Disposition to issuer (D): 22,278 (derivative) · Disposition to issuer (D): 17,000 (derivative) | EDGAR |
| 2024-02-13 | 4 | PepGen Inc. (PEPG) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter, Shah Rajeev M. | Purchase (P): 2,557,593 @ $10.64 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1825376 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →